Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 2/20 | 0.47 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.42 |
| ▸ | GAA | P10253 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | NQO2 | P16083 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32889381 | 0.80 | KEAP1 (0.50) | KEAP1NFE2L2KDRALDH1A1KDM4E | |
| SCHEMBL370588 | 0.80 | KEAP1 (0.50) | KEAP1NFE2L2KDRALDH1A1KDM4E | |
| SCHEMBL15373471 | 0.80 | NR1I2 (0.51) | KEAP1NFE2L2KDRALDH1A1KDM4E | |
| SCHEMBL12475636 | 0.80 | KEAP1 (0.50) | KEAP1NFE2L2KDRALDH1A1KDM4E | |
| SCHEMBL27818359 | 0.79 | KDR (0.40) | KEAP1NFE2L2KDRALDH1A1KDM4E | |
| SCHEMBL15704609 | 0.77 | HPGD (0.47) | KEAP1NFE2L2ALDH1A1KDM4EGAA | |
| SCHEMBL3524315 | 0.77 | KEAP1 (0.47) | KEAP1NFE2L2KDRALDH1A1KDM4E | |
| SCHEMBL2535316 | 0.77 | KEAP1 (0.51) | KEAP1NFE2L2KDRALDH1A1KDM4E | |
| SCHEMBL16065330 | 0.77 | DAO (0.37) | RXFP1NR1I2NPSR1CYP1A2ESR1 | |
| SCHEMBL27818358 | 0.76 | NR1I2 (0.42) | KEAP1NFE2L2KDRALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 413 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118221577-A | 2-Phenoxyquinoline derivative, and preparation method and application thereof | 湖南中医药大学 | 2024-06-21 | — | — | CN | claimed |
| CN-111166750-B | Novel antibacterial application of 4-fluoro-2-methylindole compound | 四川大学 | 2022-12-27 | — | — | CN | claimed |
| CN-110386892-B | Preparation method of 4-fluoro-5-hydroxy-2-methyl-1H-indole | 新发药业有限公司 | 2020-08-18 | — | — | CN | claimed |
| CN-111166750-A | Novel antibacterial application of 4-fluoro-2-methylindole compound | 四川大学 | 2020-05-19 | — | — | CN | claimed |
| US-8492560-B2 | Quinazoline derivatives as angiogenesis inhibitors | ASTRAZENECA AB (SE) | 2013-07-23 | — | — | US | claimed |
| EP-2540705-A2 | Process for preparing indol-5-oxy-quinazoline derivatives and intermediates | AstraZeneca AB (Publ) (SE) | 2013-01-02 | — | — | EP | claimed |
| EP-2540706-A2 | PROCESS FOR PREPARING INDOL-5-OXY-QUINAZOLINE DERIVATIVES AND INTERMEDIATES | AstraZeneca AB (Publ) (SE) | 2013-01-02 | — | — | EP | claimed |
| US-8293902-B2 | Quinazoline compounds | ASTRAZENECA AB (SE) | 2012-10-23 | — | — | US | claimed |
| US-20120197027-A1 | Quinazoline Derivatives as Angiogenesis Inhibitors | STOKES ELAINE S E (GB) | 2012-08-02 | — | — | US | claimed |
| CN-102532108-A | Process for preparing indol-5-oxy-quinazoline derivatives and intermediates | ASTRAZENECA AB | 2012-07-04 | — | — | CN | claimed |
| CN-101528688-A | Process for preparing indole-5-oxoquinazoline derivatives and intermediates | ASTRAZENECA AB (SE) | 2009-09-09 | — | — | CN | claimed |
| EP-2050744-A1 | Quinazoline derivatives as angiogenesis inhibitors | AstraZeneca AB (SE) | 2009-04-22 | — | — | EP | claimed |
| US-20080221322-A1 | CHEMICAL PROCESS | ASTRAZENECA AB (SE) | 2008-09-11 | — | — | US | claimed |
| WO-2008053221-A2 | PROCESS FOR PREPARING INDOL- 5 -OXY- QUINAZOLINE DERIVATIVES AND INTERMEDIATES | ASTRAZENECA AB (SE) | 2008-05-08 | — | — | WO | claimed |
| US-20080027069-A1 | Quinazoline compounds | ASTRAZENECA AB | 2008-01-31 | — | — | US | claimed |
| CN-100360505-C | Quinazoline derivatives as angiogenesis inhibitors | ASTRAZENECA AB (SE) | 2008-01-09 | — | — | CN | claimed |
| US-7244729-B2 | 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives | NOVARTIS AG (CH) | 2007-07-17 | — | — | US | claimed |
| US-20060004017-A1 | Quinazoline derivatives as angiogenesis inhibitors | ASTRAZENECA AB | 2006-01-05 | — | — | US | claimed |
| EP-1553097-A1 | QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS AND INTERMEDIATES THEREFORE | AstraZeneca AB (SE) | 2005-07-13 | — | — | EP | claimed |
| CN-1597667-A | Quinazoline derivatives as angiogenesis inhibitors | ASTRAZENECA AB (SE) | 2005-03-23 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120197027-A1 | Quinazoline Derivatives as Angiogenesis Inhibitors | VEGFA, FLT1, KDR | KEAP1 1497/4885NFE2L2 1817/4885KDR 3/4885 |
| US-20080027069-A1 | Quinazoline compounds | VEGFA, FLT4, FLT1 | KEAP1 2163/4885NFE2L2 2540/4885KDR 5/4885 |
| US-20060004017-A1 | Quinazoline derivatives as angiogenesis inhibitors | FLT4, NOS3, FLT1 | KEAP1 1076/4885NFE2L2 1009/4885KDR 4/4885 |
| US-20080221322-A1 | CHEMICAL PROCESS | CYP3A5, CYP3A4, CYP3A7 | KEAP1 475/4885NFE2L2 1848/4885KDR 3684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.